Rebecca Weil
Corporate Officer/Principal at OCULIS HOLDING AG
Profile
Rebecca Weil is currently the Chief Commercial Officer at Oculis Holding AG.
Prior to her current position, she held various roles including Director at Juvenile Diabetes Research Foundation (New York), Global Head-Marketing, Strategy & Pharmaceuticals at Bausch + Lomb Corp., and Head-Regional Franchise Asia, Middle East & Africa at Novartis AG.
From 2019 to 2023, she served as the Head-Global Marketing at Idorsia Ltd.
Before that, she was the Group Vice President & Head-Corporate Affairs at Shire Plc from 2018 to 2019.
Rebecca also worked as the Vice President & Head-Western Europe at Alcon AG.
She holds a doctorate degree from Massachusetts Institute of Technology and an undergraduate degree from Princeton University.
Rebecca Weil active positions
| Companies | Position | Start |
|---|---|---|
| OCULIS HOLDING AG | Corporate Officer/Principal | 2023-09-10 |
Former positions of Rebecca Weil
| Companies | Position | End |
|---|---|---|
| IDORSIA LTD | Sales & Marketing | 2023-07-31 |
| SHIRE | Corporate Officer/Principal | 2019-02-28 |
| Juvenile Diabetes Research Foundation (New York) | Director/Board Member | - |
| BAUSCH + LOMB CORPORATION | Sales & Marketing | - |
| NOVARTIS AG | Corporate Officer/Principal | - |
Training of Rebecca Weil
| Massachusetts Institute of Technology | Doctorate Degree |
| Princeton University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| OCULIS HOLDING AG | Health Technology |
| IDORSIA LTD | Health Technology |
| ALCON INC. | Health Technology |
| NOVARTIS AG | Health Technology |
| BAUSCH + LOMB CORPORATION | Health Technology |
| Private companies | 2 |
|---|---|
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
| Juvenile Diabetes Research Foundation (New York) |
- Stock Market
- Insiders
- Rebecca Weil
